Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey
JOURNAL OF GYNECOLOGIC ONCOLOGY(2024)
Abstract
Objective: To identify the adherence rate to poly (ADP -ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. Methods: The adherence rate to PARP inhibitors was calculated using self -reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence. Results: Of the 131 respondents, 32 (24.4%) showed non -adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality -oflife assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p<0.001) were associated with high adherence to PARP inhibitors. Conclusion: Approximately one-fourth of patients with ovarian cancer are non -adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.
MoreTranslated text
Key words
Ovarian Cancer,PARP Inhibitor,Compliance,Survey
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined